Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 13,610 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed Phase 1 Interventional

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT04703920
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
Interventions
Talazoparib, Belinostat
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Nov 3, 2026, 5:46 PM EST
Terminated Phase 2 Interventional Results available

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Vinorelbine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Nov 3, 2026, 5:46 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

NCT02807597
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery
Drug · Device · Procedure
Lead sponsor
Samuel Achilefu
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Nov 3, 2026, 5:46 PM EST
Not listed Phase 2 Interventional

To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

NCT05135910
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Hallux Terbinafine Subungual Gel
Drug
Lead sponsor
Hallux, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Mesa, Arizona • Parker, Colorado • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Nov 3, 2026, 5:46 PM EST
Completed Not applicable Interventional

Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain

NCT04075097
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Neuropathic Pain
Interventions
Aerobic exercise, Iyengar yoga
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Nov 3, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

NCT06318897
View directory record Official record
Conditions
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 3, 2026, 5:46 PM EST
Completed Not applicable Interventional Results available

Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia

NCT02460497
View directory record Official record
Conditions
Female Pattern Hair Loss, Androgenic Alopecia
Interventions
Treatment: Minoxidil 2% / Botanical Hair Solution for Women
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Nov 3, 2026, 5:46 PM EST
Not listed Phase 1 Interventional

Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema

NCT00318513
View directory record Official record
Conditions
Lymphedema
Interventions
Bevacizumab
Drug
Lead sponsor
Premiere Oncology of Arizona
Other
Eligibility
0 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 10, 2006 · Synced Nov 3, 2026, 5:46 PM EST
Completed Not applicable Interventional

Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation

NCT00579800
View directory record Official record
Conditions
Breast Cancer
Interventions
new software sequences, FIESTA and Vibrant-DE and IDEAL
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

NCT04532164
View directory record Official record
Conditions
Dermatitis, Photoallergic
Interventions
Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Nov 3, 2026, 5:46 PM EST
Completed Not applicable Interventional

A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders

NCT01765309
View directory record Official record
Conditions
Breast Cancer
Interventions
Bilateral mastectomy with reconstruction
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Nov 3, 2026, 5:46 PM EST
Withdrawn Phase 1 Interventional

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

NCT06229392
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Triple Negative
Interventions
Fluzone Quadrivalent
Biological
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 3, 2026, 5:46 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

NCT03671044
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
Drug
Lead sponsor
Jina Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Columbus, Georgia • Springfield, Missouri • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 1Phase 2 Interventional Results available

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

NCT00952692
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
dHER2 + AS15 ASCI, Lapatinib
Biological · Drug
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 2Phase 3 Interventional

Etanercept for Wegener's Granulomatosis

NCT00005007
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
11 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Nov 3, 2026, 5:46 PM EST
Completed No phase listed Observational Accepts healthy volunteers

The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study

NCT01942564
View directory record Official record
Conditions
Head Injury, Traumatic Brain Injury (TBI), Photosensitivity, Photophobia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Nov 3, 2026, 5:46 PM EST
Completed Not applicable Interventional Results available

Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses

NCT01523899
View directory record Official record
Conditions
Cutaneous Abscess
Interventions
Xpert MRSA/SA SSTI, Standard culture
Device · Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 2 Interventional Results available

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Bevacizumab, Everolimus
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 3, 2026, 5:46 PM EST
Recruiting Not applicable Interventional

Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

NCT07179809
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Demographics/Lifestyle Survey
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 5:46 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Nov 3, 2026, 5:46 PM EST
Completed Phase 2 Interventional Results available

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

NCT02509598
View directory record Official record
Conditions
Rhabdomyosarcoma, Melanoma
Interventions
Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
Drug · Procedure
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Nov 3, 2026, 5:46 PM EST